29,705 results match your criteria hbsag


An update on oral drug delivery intestinal lymphatic transport.

Acta Pharm Sin B 2021 Aug 9;11(8):2449-2468. Epub 2021 Apr 9.

Key Laboratory of Smart Drug Delivery of MOE, School of Pharmacy, Fudan University, Shanghai 201203, China.

Orally administered drug entities have to survive the harsh gastrointestinal environment, penetrate the enteric epithelia and circumvent hepatic metabolism before reaching the systemic circulation. Whereas the gastrointestinal stability can be well maintained by taking proper measures, hepatic metabolism presents as a formidable barrier to drugs suffering from first-pass metabolism. The pharmaceutical academia and industries are seeking alternative pathways for drug transport to circumvent problems associated with the portal pathway. Read More

View Article and Full-Text PDF

Oral delivery of proteins and peptides: Challenges, status quo and future perspectives.

Acta Pharm Sin B 2021 Aug 29;11(8):2416-2448. Epub 2021 Apr 29.

Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai 200443, China.

Proteins and peptides (PPs) have gradually become more attractive therapeutic molecules than small molecular drugs due to their high selectivity and efficacy, but fewer side effects. Owing to the poor stability and limited permeability through gastrointestinal (GI) tract and epithelia, the therapeutic PPs are usually administered by parenteral route. Given the big demand for oral administration in clinical use, a variety of researches focused on developing new technologies to overcome GI barriers of PPs, such as enteric coating, enzyme inhibitors, permeation enhancers, nanoparticles, as well as intestinal microdevices. Read More

View Article and Full-Text PDF

[The relationship between serum HBV pgRNA and antigen status in patients with chronic hepatitis B after long-term nucleotide analogues treatment].

Zhonghua Gan Zang Bing Za Zhi 2021 Aug;29(8):766-770

Department of Infectious Diseases, the First Affiliated Hospital of Nanchang University, Nanchang 330006, China.

To study the relationship between serum HBV pgRNA and antigen status in patients with chronic hepatitis B treated with long-term nucleotide analogues, and to elucidate the reason and possible mechanism of high relapse rate in antiviral therapy of nucleotide analogues in chronic hepatitis B. 94 patients with chronic hepatitis B who had been treated with long-term antiviral therapy with nucleotide analogues (more than 2 years) were divided into 5 groups according to their HBeAg and HBsAg levels: e antigen positive group(group1), e antigen negative and HBsAg > 1 500 IU/L group(group2), e antigen negative and 100 IU/L< HBsAg < 1 500 IU/L group(group3), e antigen negative and HBsAg < 100 IU/L group(group4), e antigen negative and HBsAg negative group(group5). The level and detection rate of HBVpgRNA in different antigen states groups were analyzed and compared. Read More

View Article and Full-Text PDF

[Progress in prevention and control of viral hepatitis since the establishing of the People's Republic of China].

Authors:
F Q Cui H Zhuang

Zhonghua Gan Zang Bing Za Zhi 2021 Aug;29(8):725-731

School of Basic Medicine, Peking University, Beijing 100191, China.

China has the highest disease burden of viral hepatitis. After understanding the epidemic characteristics of viral hepatitis in China and putting forward scientific prevention and control strategies, the Chinese government has been effectively practicing the policy of "prevention first with combination of prevention and control". Over the past 40 years, China has taken effective measures to promote vaccination, strengthen blood screening, standardize diagnosis and treatment services and strengthen supervision, and achieved remarkable success. Read More

View Article and Full-Text PDF

Efficient Inhibition of Hepatitis B Virus Replication and cccDNA Formation by HBV Ribonuclease H Inhibitors During Infection.

Antimicrob Agents Chemother 2021 Sep 13:AAC0146021. Epub 2021 Sep 13.

Department of Molecular Microbiology and Immunology, School of Medicine, Saint Louis University, Saint Louis, MO USA.

The Hepatitis B Virus (HBV) ribonuclease H (RNase H) is an attractive but unexploited drug target. Here, we addressed three limitations to the current state of RNase H inhibitor development: i) Efficacy has been assessed only in transfected cell lines; ii) Cytotoxicity data are from transformed cell lines rather than primary cells; and iii) It is unknown how the compounds work against nucleos(t)ide analog resistant HBV strains. Three RNase H inhibitors from different chemotypes, (α-hydroxytropolone), (N-hydroxypyridinedione), and (N-hydroxynapthyridinone), were tested in HBV-infected HepG2-NTCP cells for inhibition of cccDNA accumulation and HBV product formation. Read More

View Article and Full-Text PDF
September 2021

Effects of on-treatment ALT flares on serum HBsAg and HBV RNA in patients with chronic HBV infection.

J Viral Hepat 2021 Sep 12. Epub 2021 Sep 12.

Toronto Centre for Liver Disease, University Health Network, Toronto, ON, Canada.

As pegylated interferon-alpha (PEG-IFN-α) is increasingly used in combination regimens of novel drugs, we aimed to characterize ALT flares and their relationship with serum HBsAg and HBV RNA kinetics in a large, combined cohort of chronic hepatitis B (CHB) patients on PEG-IFN-α-based therapy. In this post hoc analysis of four international randomized trials, 269/130/124/128 patients on PEG-IFN-α monotherapy, PEG-IFN-α plus nucleos(t)ide analogue (NA) de novo combination, PEG-IFN-α add-on to NA, or NA monotherapy were included, respectively. A flare was defined as an episode of ALT ≥5×ULN. Read More

View Article and Full-Text PDF
September 2021

A case of child-to-father transmission of hepatitis B virus in Japan: a rare infection route.

Clin J Gastroenterol 2021 Sep 12. Epub 2021 Sep 12.

Department of Virology and Liver Unit, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.

This report describes a rare horizontal transmission of hepatitis B virus (HBV) from an unvaccinated 6-year-old boy to his father. The father had been diagnosed with acute hepatitis B 1 month earlier; therefore, when the child visited the clinic with fever, he was screened for HBV markers and diagnosed as an asymptomatic carrier. Neither the child nor his father was vaccinated against HBV, whereas the child's mother and sister, having received the HBV vaccination as they were medical staff and a nursing student, respectively, tested negative for the hepatitis B surface antigen (HBsAg) and positive for anti-HBs. Read More

View Article and Full-Text PDF
September 2021

Auxiliary Liver Graft Can Be Protected From HBV Infection in HBsAg Positive Blood Circulation.

Front Med (Lausanne) 2021 25;8:726502. Epub 2021 Aug 25.

Beijing Friendship Hospital, Capital Medical University, Beijing, China.

Auxiliary grafts have a high risk of Hepatitis B virus (HBV) infection in patients with chronic HBV-related diseases. Hepatitis B virus-related auxiliary partial orthotopic liver transplantation (APOLT) cases were reviewed to show the results of current methods to block native-to-graft HBV transmission. Three patients received APOLT for HBV-related liver cirrhosis and a recurrent upper gastrointestinal hemorrhage between April 2015 and January 2017 by the liver transplant team of Beijing Friendship Hospital affiliated with Capital Medical University. Read More

View Article and Full-Text PDF

Hepatocellular carcinoma in a non-cirrhotic liver with a tumor thrombus.

Clin Case Rep 2021 Sep 7;9(9):e04800. Epub 2021 Sep 7.

Kilimanjaro Christian Medical University College Moshi Tanzania.

Young adults with HCC tend to have a poor prognosis because of advanced disease despite preserved liver function. Screening and early diagnosis for HCC are needed for young adults to demonstrate an improved prognosis, especially in HBsAg positive patients. Read More

View Article and Full-Text PDF
September 2021

Follicular Helper T (T) Cell Targeting by TLR8 Signaling For Improving HBsAg-Specific B Cell Response In Chronic Hepatitis B Patients.

Front Immunol 2021 26;12:735913. Epub 2021 Aug 26.

Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, United States.

Identifying signaling pathways that induce B cell response can aid functional cure strategies for chronic hepatitis B infection (CHB). TLR8 activation with ssRNA was shown to enhance follicular helper T cell (T) function leading to improved B cell responses . We investigated whether this mechanism can rescue an exhausted immune response in CHB infection. Read More

View Article and Full-Text PDF

Seroprevalence and Associated Factors of Hepatitis B and C Virus Among Pulmonary Tuberculosis Patients Attending Health Facilities in Gondar Town, Northwest Ethiopia.

Infect Drug Resist 2021 3;14:3599-3608. Epub 2021 Sep 3.

Department of Medical Microbiology, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.

Background: Hepatitis B virus (HBV) and hepatitis C virus (HCV) are hepatotropic viruses whose primary replication occurs in the liver. Despite the significant clinical importance of early screening of hepatitis B and C virus infection in decreasing the hepatotoxicity effect of anti-tuberculosis drugs, screening of hepatitis B and C virus among tuberculosis (TB) patients before treatment has not been practiced in Ethiopia. Thus, this study was conducted to determine the seroprevalence and associated factors of HBV and HCV infections among pulmonary TB (PTB) patients attending health facilities in Gondar, Northwest Ethiopia. Read More

View Article and Full-Text PDF
September 2021

Improvement of hepatitis B vaccine to induce IFN-γ cytokine response: A new formulation.

Microb Pathog 2021 Sep 8:105184. Epub 2021 Sep 8.

Recombinant Vaccine Research Center, Tehran University of Medical Sciences, Tehran, Iran; Immunotherapy Group, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran; Department of Immunology, Pasteur Institute of Iran, Tehran, Iran. Electronic address:

Hepatitis B virus (HBV) infection is limited through vaccination against HBsAg formulated in the Alum adjuvant. However, this alum-formulated vaccine fails to be preventive in some cases, also known as non-responders. Recent studies have shown the immunomodulatory effect of α-tocopherol in various models. Read More

View Article and Full-Text PDF
September 2021

Hepatitis B And C Screening In Hospitalized Patients With Sars-Cov-2 Infection.

Gastroenterol Hepatol 2021 Sep 8. Epub 2021 Sep 8.

Servicio de Aparato Digestivo. Complejo Asistencial Universitario de León, Calle Altos de Nava s/n, 24001, León, España; Instituto Universitario de Biomedicina (IBIOMED), Universidad de León, León, España; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain. Electronic address:

Aims: To evaluate the results of a hepatitis B and C screening program in hospitalized COVID-19 patients.

Method: Transversal prospective study conducted in two Spanish hospitals. Patients admitted from March 1st to December 31st 2020 with a diagnosis of COVID-19 were tested for markers of hepatitis B (HBsAg, anti-HBc) and C (anti-HCV, HCV RNA) infection. Read More

View Article and Full-Text PDF
September 2021

Occult Hepatitis B Infection in End-Stage Renal Disease Patients Starting Maintenance Hemodialysis at a Tertiary Care Hospital: A Descriptive Cross-sectional Study.

JNMA J Nepal Med Assoc 2021 Apr 30;59(236):336-341. Epub 2021 Apr 30.

Department of Gastroenterology and Hepatology, BP Koirala Institute of Health Sciences, Dharan, Nepal.

Introduction: Occult hepatitis B infection is defined as the presence of the hepatitis B virus deoxyribonucleic acid in liver tissues and/or serum in the absence of serum hepatitis B Virus surface antigen. The prevalence of occult hepatitis B infection in end-stage renal disease patients is largely unknown. The aim of the study is to determine the prevalence of occult hepatitis B infection in the hemodialysis population starting maintenance hemodialysis. Read More

View Article and Full-Text PDF

Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib.

Int J Rheum Dis 2021 Sep 10. Epub 2021 Sep 10.

Division of Allergy, Immunology and Rheumatology, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan.

Objectives: The aim of this study was to investigate hepatitis B virus (HBV) reactivation in patients with rheumatoid arthritis (RA) receiving tofacitinib.

Method: This was a retrospective study performed in a regional teaching hospital in southern Taiwan. During January 2017 and December 2020, patients with a clinician-confirmed diagnosis of RA using tofacitinib for at least 3 months were enrolled. Read More

View Article and Full-Text PDF
September 2021

High Risk of Viral Reactivation in Hepatitis B Patients with Systemic Lupus Erythematosus.

Int J Mol Sci 2021 Aug 24;22(17). Epub 2021 Aug 24.

Division of Gastroenterology, Department of Medicine, Taipei Veterans General Hospital, Taipei 11217, Taiwan.

HBV reactivation (HBVr) can occur in hepatitis B surface antigen (HBsAg)-positive and negative patients. Here, we determined the incidence of HBVr and its related hepatitis in patients with systemic lupus erythematosus (SLE). From 2000 to 2017, 3307 SLE cases were retrospectively reviewed for episodes of hepatitis. Read More

View Article and Full-Text PDF

Hepatitis B Viral Markers in the Human Milk of HBsAg-Positive Mothers: An Observational Study.

J Hum Lact 2021 Sep 8:8903344211043066. Epub 2021 Sep 8.

Department of Laboratory Medicine and Jiangsu Key Laboratory for Molecular Medicine, Nanjing Drum Tower Hospital, Nanjing University Medical School, Jiangsu, China.

Background: Quantification of viral antigens and viral loads in human milk samples from mothers infected with hepatitis B virus is largely unknown.

Research Aim: The aim of the study was to quantitatively measure the levels of viral antigens and deoxyribonucleic acid of hepatitis B virus in human milk from mothers infected with hepatitis B virus.

Methods: Fifty-five pairs of milk and serum samples from mothers with positive hepatitis B surface antigen, including 11 hepatitis B e antigen positive, were quantitatively tested to measure viral antigens by microparticle enzyme immunoassay and viral loads by real-time polymerase chain reaction assay. Read More

View Article and Full-Text PDF
September 2021

Kinetics of quantitative hepatitis B surface antigen in patients with rheumatic disease and chronic hepatitis B receiving biologic agents.

J Viral Hepat 2021 Sep 8. Epub 2021 Sep 8.

Clinical Immunology-Rheumatology Unit, 2nd Department of Medicine and Laboratory, National and Kapodistrian University of Athens School of Medicine, Hippokration General Hospital, Athens, Greece.

The effect of biologic treatment on quantitative Hepatitis B surface Antigen (qHBsAg) levels and HBsAg clearance in rheumatic patients with chronic HBV infection has not been well studied. We prospectively followed rheumatic patients with HBeAg-negative chronic HBV infection (n=28) treated with biologics and oral antivirals, categorized into patients with chronic hepatitis B (CHB, group A n=13) and chronic HBV infection (group B n=15) and matched them to appropriate non-rheumatic controls. qHBsAg kinetics were serially measured and compared between groups. Read More

View Article and Full-Text PDF
September 2021

Optimizing Hepatitis B Virus Screening in the United States Using a Simple Demographics-Based Model.

Hepatology 2021 Sep 8. Epub 2021 Sep 8.

Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, CA, United States.

Background & Aims: Chronic hepatitis B (CHB) affects over 290 million people globally and only 10% have been diagnosed, presenting a severe gap that must be addressed. We developed logistic regression and machine learning (random forest) models to accurately identify patients with HBV, using only easily-obtained demographic data from a population-based data set.

Approach & Results: We identified participants with data on hepatitis B surface antigen (HBsAg), birth year, sex, race/ethnicity, and birthplace from 10 cycles of the National Health and Nutrition Examination Survey (NHANES, 1999-2018) and divided them into two cohorts: training (cycles 2, 3, 5, 6, 8, 10; n = 39,119) and validation (cycles 1, 4, 7, 9; n = 21,569). Read More

View Article and Full-Text PDF
September 2021

Hepatitis B virus genotypes prevalence in patients from hepatology services in Ceará, Brazil.

Rev Soc Bras Med Trop 2021 6;54:e08072020. Epub 2021 Sep 6.

Universidade Federal do Ceará, Departamento de Patologia, Programa de Pós-Graduação em Patologia, Fortaleza, CE, Brasil.

Introduction: Hepatitis B virus (HBV) infection is a public health problem; therefore, we aimed to report HBV genotypes in Ceará, Brazil.

Methods: A total of 103 HBsAg-positive samples were subjected to HBV genotyping and subgenotyping.

Results: The following genetic compositions of samples were found: F-54% (F2-83. Read More

View Article and Full-Text PDF
September 2021

Discontinuation of nucleot(s)ide analogue therapy in HBeAg-negative chronic hepatitis B: a meta-analysis.

Gut 2021 Sep 7. Epub 2021 Sep 7.

Gastroenterology Department, St Vincent's Hospital Melbourne Pty Ltd, Fitzroy, Victoria, Australia.

Background And Aims: Sustained virological suppression and hepatitis B surface antigen (HBsAg) loss have been described after nucleot(s)ide analogue (NA) discontinuation for patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB). We performed a meta-analysis of the clinical outcomes after NA discontinuation for HBeAg-negative CHB.

Methods: Studies involving NA cessation in HBeAg-negative CHB individuals with a median follow-up of ≥12 months were included. Read More

View Article and Full-Text PDF
September 2021

Determinants of Hepatitis B Virus (HBV) Infection Among University Students in Central Bangladesh.

J Community Health 2021 Sep 7. Epub 2021 Sep 7.

Department of Public Health, Faculty of Allied Health Sciences, Daffodil International University (DIU), Dhaka, Bangladesh.

This study aimed to determine the seroprevalence and determinants of hepatitis B virus (HBV) infection among university students in Bangladesh. This cross-sectional study was conducted among 614 students from five universities in central Bangladesh. Data were collected on demographic information, immunization history, medical and blood transfusion history through the face-to-face interview. Read More

View Article and Full-Text PDF
September 2021

Characterization of T cell immunity in chronic hepatitis B virus-infected mothers with postpartum alanine transaminase flare.

BMC Infect Dis 2021 Sep 6;21(1):922. Epub 2021 Sep 6.

Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.

Background: Postpartum alanine transaminase (ALT) flares occur frequently in chronic hepatitis B virus (HBV)-infected mothers with antepartum antiviral therapy (AVT). We aimed to characterize the T cell immunity in HBV-infected mothers experiencing postpartum ALT flares.

Methods: Twenty HBV-infected pregnant women who received AVT at 26-28 weeks of gestation were enrolled and followed up until 15-18 weeks postpartum. Read More

View Article and Full-Text PDF
September 2021

Pacbio Sequencing of PLC/PRF/5 Cell Line and Clearance of HBV Integration Through CRISPR/Cas-9 System.

Front Mol Biosci 2021 17;8:676957. Epub 2021 Aug 17.

Department of Microbiology and Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China.

The integration of HBV DNA is one of the carcinogenic mechanisms of HBV. The clearance of HBV integration in hepatocyte is of great significance to cure chronic HBV infection and thereby prevent the occurrence of HBV-related hepatocellular carcinoma (HCC). However, the low throughput of traditional methods, such as Alu-PCR, results in low detecting sensitivity of HBV integration. Read More

View Article and Full-Text PDF

Hepatitis B Core-Related Antigen is a Biomarker for off-Treatment Relapse After Long-Term Nucleos(t)ide Analog Therapy in Patients with Chronic Hepatitis B.

Int J Gen Med 2021 28;14:4967-4976. Epub 2021 Aug 28.

Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, People's Republic of China.

Objective: It remains unknown how to stratify the risk of clinical relapse of chronic hepatitis B (CHB) patients after stopping nucleos(t)ide analogs (NAs) antiviral therapy.

Methods: The current post hoc analysis included 122 non-cirrhotic patients with chronic hepatitis B virus infection who were positive for hepatitis B envelope antigen (HBeAg) and discontinued long-term NA therapy after achieving HBeAg seroconversion for a median of 2.5 years. Read More

View Article and Full-Text PDF

Asociación Mexicana de Hepatología A.C. Clinical guideline on hepatitis B.

Rev Gastroenterol Mex (Engl Ed) 2021 Sep 3. Epub 2021 Sep 3.

Clínica Lomas Altas, Mexico City, Mexico.

Hepatitis B virus (HBV) infection continues to be a worldwide public health problem. In Mexico, at least three million adults are estimated to have acquired hepatitis B (total hepatitis B core antibody [anti-HBc]-positive), and of those, 300,000 active carriers (hepatitis B surface antigen [HBsAg]-positive) could require treatment. Because HBV is preventable through vaccination, its universal application should be emphasized. Read More

View Article and Full-Text PDF
September 2021

Long-term safety of rituximab in rheumatic patients with previously resolved hepatitis B virus infection.

Intern Emerg Med 2021 Sep 2. Epub 2021 Sep 2.

Rheumatology Unit, Department of Emergency and Organ Transplantation (D.E.T.O.), University of Bari, Bari, Italy.

Conflicting results can be found in the literature on the frequency of hepatitis B virus (HBV) reactivation (HBVr) on rituximab (RTX) in rheumatic patients with previously resolved HBV (prHBV) infection. Here, we report the frequency of HBVr in a large historical cohort of caucasian rheumatic patients with prHBV receiving RTX. Registry data of rheumatic patients treated with RTX were retrospectively analysed. Read More

View Article and Full-Text PDF
September 2021

Substantial gaps in evaluation and treatment of patients with hepatitis B in the US.

J Hepatol 2021 Aug 30. Epub 2021 Aug 30.

Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, CA, United States; Department of Epidemiology and Population Health, Stanford, California, United States. Electronic address:

Background And Aims: HBV associated liver complication is reduced by antiviral therapy. Prior studies using local institutional cohorts have suggested suboptimal evaluation and treatment. We aimed to determine the proportion of patients with chronic HBV infection who received adequate evaluation, were treatment eligible, and received antiviral treatment using a large, nationwide cohort. Read More

View Article and Full-Text PDF

On-treatment HBV RNA dynamic predicts entecavir-induced HBeAg seroconversion in children with chronic hepatitis B.

J Infect 2021 Aug 30. Epub 2021 Aug 30.

Department of Laboratory Medicine, Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Guilin, China.

Background: Hepatitis B e antigen (HBeAg) seroconversion is an important intermediate outcome in HBeAg-positive chronic hepatitis B patients. This study aimed to explore whether hepatitis B virus (HBV) RNA serum levels can predict HBeAg seroconversion treated with entecavir.

Methods: Serum samples from HBeAg-positive children previously treated with entecavir were retrospectively analyzed. Read More

View Article and Full-Text PDF

In silico analysis of mutations associated with occult hepatitis B virus (HBV) infection in South Africa.

Arch Virol 2021 Sep 1. Epub 2021 Sep 1.

Division of Digestive Diseases, University of Cincinnati College of Medicine, ML 0595, Albert Sabin Way, Cincinnati, OH, 45267-0595, USA.

Occult hepatitis B virus (OBI) infection is defined by the presence of viral DNA in the liver and/or serum in absence of hepatitis B surface antigen (HBsAg). While multiple studies have identified mutations that are associated with OBI, only a small portion of these mutations have been functionally characterized in vitro. Using complementary in silico approaches, the effects of OBI-associated amino acid mutations on HBV protein function in HBV/HIV-positive ART-naïve South Africans were evaluated. Read More

View Article and Full-Text PDF
September 2021